<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01212367</url>
  </required_header>
  <id_info>
    <org_study_id>UPCC 18508; 808806</org_study_id>
    <secondary_id>P01CA066726</secondary_id>
    <nct_id>NCT01212367</nct_id>
  </id_info>
  <brief_title>Intrapleural Gene Transfer for Pleural Mesothelioma</brief_title>
  <acronym>IFN-alpha</acronym>
  <official_title>A Pilot Study of Repeated Dose Intrapleural Adenoviral-Mediated Interferon-Alpha (SCH 721015, Ad.hIFN-a2b) Gene Transfer for Malignant Pleural Mesothelioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abramson Cancer Center of the University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Abramson Cancer Center of the University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research will study how to activate the immune system by using gene transfer. Gene&#xD;
      transfer involves inserting a specially designed gene into cancer cells. A gene is a part of&#xD;
      the genetic code that instructs the cells of our bodies to produce specific compounds&#xD;
      (proteins) important for the makeup or function of the cell. The study hypothesis is that&#xD;
      repeated doses of SCH 721015 given over a three day interval would result in gene transfer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ad.hIFN-α (SCH 721015, adenoviral-mediated interferon alpha) is a replication-defective&#xD;
      recombinant adenoviral vector containing the human interferon-alpha (hIFN-alpha) gene. This&#xD;
      Phase I study is designed to evaluate the safety and maximum tolerated dose (MTD) of two&#xD;
      doses of Ad.hIFN-alpha injected into the pleural (intrapleural, IP) and given 4 days apart in&#xD;
      subjects with pleural mesothelioma.&#xD;
&#xD;
      Subjects who meet eligibility will have a pleural catheter placed 2 weeks prior to the first&#xD;
      dose. Subjects are then admitted to the research center on Days 1 and 4 for dosing and&#xD;
      overnight observation. Subjects are then followed-up as outpatients for a total of 6 months.&#xD;
      Radiographic evaluations are repeated on Day 64 and at 6 months. The pleural catheter is&#xD;
      removed once it is not necessary.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To analyze gene transfer with two does separated by three-day interval</measure>
    <time_frame>After the first dose and at each visit until day 94</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Malignant Pleural Mesothelioma</condition>
  <arm_group>
    <arm_group_label>Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a dose de escalation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SCH 721015</intervention_name>
    <description>1.0 x 10e12 viral particles on Days 1 and 4</description>
    <arm_group_label>Dose Level 1</arm_group_label>
    <other_name>Adenoviral-mediated Interferon-alpha</other_name>
    <other_name>Ad.IFN-alpha</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SCH 721015</intervention_name>
    <description>3.0 x 10e11 viral particles on Days 1 and 4</description>
    <arm_group_label>Dose Level 2</arm_group_label>
    <other_name>Adenoviral-mediated Interferon-alpha</other_name>
    <other_name>Ad.IFN-alpha</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  evidence of progressive disease after standard first line treatment of mesothelioma;&#xD;
             OR patient has refused standard first line treatment of mesothelioma&#xD;
&#xD;
          -  evaluable disease&#xD;
&#xD;
          -  No radiotherapy and/or treatment with chemotherapeutic, cytotoxic, or immunologic&#xD;
             agents within 14 days prior to infusion of the IFN-α vector&#xD;
&#xD;
          -  Must have a pleural space involved with tumor accessible for pleural catheter&#xD;
             insertion&#xD;
&#xD;
          -  FEV1&gt; 1 liter or 40% of predicted value&#xD;
&#xD;
          -  Must have an anti-adenoviral neutralizing antibody titer equal to or less than 1:1000.&#xD;
             This will be measured by the Penn Vector Core&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of HIV or Hepatitis B infection&#xD;
&#xD;
          -  Use of concurrent systemic steroids, immunosuppressives, or any other medications that&#xD;
             can directly or indirectly suppress the immune system&#xD;
&#xD;
          -  Presence of any other life-threatening illness, such as unstable angina, severe oxygen&#xD;
             dependence, significant chronic obstructive pulmonary disease (COPD), end stage liver&#xD;
             or renal disease&#xD;
&#xD;
          -  Presence of untreated brain metastases&#xD;
&#xD;
          -  Prior bone marrow or stem cell transplants&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Sterman</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>September 29, 2010</study_first_submitted>
  <study_first_submitted_qc>September 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2010</study_first_posted>
  <last_update_submitted>September 21, 2015</last_update_submitted>
  <last_update_submitted_qc>September 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gene transfer</keyword>
  <keyword>Immunology</keyword>
  <keyword>Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Mesothelioma, Malignant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferon alpha-2</mesh_term>
    <mesh_term>Interferon-alfa-1b</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>August 29, 2016</submitted>
    <returned>October 20, 2016</returned>
    <submitted>October 24, 2016</submitted>
    <returned>December 15, 2016</returned>
    <submitted>January 4, 2017</submitted>
    <returned>February 22, 2017</returned>
    <submitted>March 16, 2017</submitted>
    <returned>April 26, 2017</returned>
    <submitted>October 10, 2017</submitted>
    <returned>November 8, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

